Urologic operations during cytoreductive surgery for ovarian cancer

Berek, J. S.; Hacker, N F; Leuchter, Ronald S.; Lagasse, Leo D.; Byron, Ralph L.

doi:10.1016/0090-8258(80)90128-6

Cited by 41 publications

(113 citation statements)

References 0 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…The presence of residual tumour -also a prognosticator for ovarian cancer -was also detected in stages III and IV only (Anonymous, 1981;Berek et al, 1983). Even in advanced disease patients with residual tumour less than 2 cm had a significantly better outcome compared to women with a larger remaining mass (P = 0.03) (Figure 3).…”

Section: Resultsmentioning

confidence: 78%

“…Patients with papillary cancer had median survival of 42.7 months, compared with 29.1 months in serous, 11.4 months Since ascites is accepted as a well established prognostic factor for ovarian cancer, its influence on survival was analysed, but did not reveal any impact on the outcome (P = 0.2), probably due to the rare incidence of ascites on the whole (21.7%) in stages III and IV only (Anonymous, 1981;Berek et al, 1983).…”

Section: Resultsmentioning

confidence: 99%

“…On the other hand ascites -a strong prognosticator in ovarian cancer (Anonymous, 1981;Berek et al, 1983) (Table IV). Patients with stage III and IV were also analysed as one group with advanced disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Primary carcinoma of the fallopian tube – a retrospective analysis of 115 patients

Rosen¹,

Klein²,

Lahousen³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 78%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Primary carcinoma of the fallopian tube – a retrospective analysis of 115 patients

Rosen¹,

Klein²,

Lahousen³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

“…In published series, the technical success rates of SCR vary widely, from 37-47% 8,10,12 to 83%, 14 although the latter rate lacks credibility. The SCR procedures include enterolysis, visualization of all peritoneal surface, examination and removal of multiple histologic specimens, and intraperitoneal or retroperitoneal tumor resection.…”

Section: Surgical Techniques Of Scr and Outcome Determinantsmentioning

confidence: 99%

“…In 1983, Berek et al were the first investigators to demonstrate that patients with recurrent EOC benefited from optimal SCR. 8 Six years later, however, a widely quoted report from the M. D. Anderson Cancer Center on a review of patients who had recurrent disease did not find any significant survival benefit from SCR. Those authors stated that, in the absence of efficacious second-line medical therapy, the value of secondary tumor-reductive surgery for recurrent EOC was limited.…”

mentioning

confidence: 99%

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?

Zang

Tang

et al. 2004

Cancer

138

View full text Add to dashboard Cite

Background: Persistent infection following endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS) is a frustrating entity for the patient and rhinologist alike. Mupirocin nasal washes have been proposed as an efficacious treatment in such patients. Two small studies have reported excellent short‐term posttreatment outcomes; however, the long‐term microbiological outcomes following treatment are not known; likewise, the rate of mupirocin‐resistance following treatment has not been explored. Methods: This was a retrospective chart review of 61 patients with Staphylococcus aureus (S. aureus)‐positive surgically‐recalcitrant CRS having undergone 0.05% mupirocin nasal rinse treatment, twice daily for 4 weeks. Specific outcomes reported included posttreatment culture results, time to first posttreatment S. aureus culture, and mupirocin‐sensitivity following treatment. Results: Of 57 patients meeting minimal posttreatment follow‐up criteria, 42 (73.7%) progressed to microbiological failure by subsequently cultured S. aureus. Mean time to first positive culture was 144 days. Of the 42 patients who progressed to microbiological relapse, full antibiotic sensitivity data was available for 41; of these, only 1 was found to subsequently harbor a mupirocin‐resistant strain of S. aureus, thus yielding a posttreatment resistance rate of 2.4%. Conclusion: Treatment with mupirocin nasal washes in S. aureus–positive, surgically recalcitrant CRS has a high microbiological failure rate, with 73.7% of patients subsequently re‐culturing S. aureus. Our current treatment regime of 0.05% nasal washes twice daily for 4 weeks is associated with a posttreatment resistance rate that is consistent with other studies of topical mupirocin use, suggesting that mupirocin washes are no more likely to induce resistance than nasal vestibule decolonization in the high‐risk medical or surgical patient. © 2011 ARS‐AAOA, LLC.

show abstract

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

Eisenkop

Friedman

Spirtos³

2000

Cancer

122

View full text Add to dashboard Cite

show abstract

Urologic operations during cytoreductive surgery for ovarian cancer

Cited by 41 publications

References 0 publications

Primary carcinoma of the fallopian tube – a retrospective analysis of 115 patients

Primary carcinoma of the fallopian tube – a retrospective analysis of 115 patients

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

Contact Info

Product

Resources

About